Preview Mode Links will not work in preview mode

Mar 27, 2018

Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast. What is needed is not just new assays, technology and ideas. It is new organisations, influencers and shared working. A generation Y approach for generation Y times.

The shape of medicines R&D has transformed. Much like the story of Hollywood studies but at an alarming rate, the industry has shifted from an in-house institution to a highly-distributed, multi-party collaboration. This brings logistical benefits as well as challenges that are discussed elsewhere. The larger question for today, however is, does the work we do in discovery and early development adequately reflect patient’s priorities?

The article was written by Chris Molloy, who is CEO at the Medicines Discovery Catapult

If you'd like to view the original article then follow the link below:

You can also download the original article pdf here:

For more information on Drug Discovery World, head to: